Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.

Purcell AR, Zhen XM, Wong J, Glastras SJ

Diabetes, obesity & metabolism20 Oct 2025Cited by 10 (Europe PMC)

PMID41334580PMCIDPMC12673429DOI10.1111/dom.70188PepBankPUB-41334580

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, semaglutide achieved the greatest body weight reduction in a subgroup analysis.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide gave the biggest weight loss among the GLP-1 drugs in a subgroup analysis.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction, semaglutide subgroup
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis identified that semaglutide achieved the greatest reductions in all outcome measures.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
Report a problemFND-4133458008
02HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, semaglutide achieved the greatest HbA1c reduction in a subgroup analysis.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide gave the biggest HbA1c drop among the GLP-1 drugs in a subgroup analysis.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction, semaglutide subgroup
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis identified that semaglutide achieved the greatest reductions in all outcome measures.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
Report a problemFND-4133458009
03HumanSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, semaglutide achieved the greatest insulin dose reduction in a subgroup analysis.
In plain wordsIn adults with type 1 diabetes and overweight, semaglutide gave the biggest cut in insulin dose among the GLP-1 drugs in a subgroup analysis.
Peptide
Semaglutide
Outcome
DecreaseInsulin dose reduction, semaglutide subgroup
Study
n: not reported in source
Comparator
Other GLP-1 receptor agonists
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis identified that semaglutide achieved the greatest reductions in all outcome measures.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
Report a problemFND-4133458010

Studies that did not test the peptide alone7

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists reduced body weight by 4.31 kg.
In plain wordsIn adults with type 1 diabetes and overweight, GLP-1 drugs combined were linked to a body weight drop of 4.31 kg.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight reduction
4.31 kg
pooled GLP-1RAs
Source sentences
Summary
GLP-1RA treatment was associated with a body weight reduction of 4.31 kg (95% CI: 3.61-5.00 kg) and a HbA1c reduction of 0.25% (95% CI: 0.18-0.32%).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458001
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists reduced HbA1c by 0.25%.
In plain wordsIn adults with type 1 diabetes and overweight, GLP-1 drugs combined were linked to an HbA1c drop of 0.25%.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
0.25%
pooled GLP-1RAs
Source sentences
Summary
GLP-1RA treatment was associated with a body weight reduction of 4.31 kg (95% CI: 3.61-5.00 kg) and a HbA1c reduction of 0.25% (95% CI: 0.18-0.32%).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458002
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists reduced insulin dosage by 9.24 U/day.
In plain wordsIn adults with type 1 diabetes and overweight, GLP-1 drugs combined were linked to a lower daily insulin dose of 9.24 units.
Peptide
Semaglutide
Outcome
DecreaseInsulin dose change
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Insulin dosage reduction
9.24 U/day
pooled GLP-1RAs
Source sentences
Summary
Across all studies, insulin dosage was reduced by 9.24 U/day (95% CI: 7.04-11.45 U/day).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458003
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists increased hypoglycaemic episodes.
In plain wordsIn adults with type 1 diabetes and overweight, low blood sugar episodes were more frequent with GLP-1 drugs combined.
Peptide
Semaglutide
Outcome
IncreaseHypoglycaemic episodes
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Measurements
Odds ratio, hypoglycaemic episodes
1.34 OR
pooled GLP-1RAs
Source sentences
Summary
Hypoglycaemic episodes were increased (OR = 1.34; 95% CI: 1.02-1.76)
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458004
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists decreased hyperglycaemic episodes.
In plain wordsIn adults with type 1 diabetes and overweight, high blood sugar episodes were less frequent with GLP-1 drugs combined.
Peptide
Semaglutide
Outcome
DecreaseHyperglycaemic episodes
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Measurements
Odds ratio, hyperglycaemic episodes
0.69 OR
pooled GLP-1RAs
Source sentences
Summary
hyperglycaemic episodes decreased (OR: 0.69, 95% CI: 0.56-0.87).
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458005
09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 1 diabetes and overweight or obesity, gastrointestinal adverse events, including nausea and vomiting, were significantly more frequent with pooled GLP-1 receptor agonists.
In plain wordsIn adults with type 1 diabetes and overweight, stomach and bowel side effects such as nausea and vomiting were more frequent with GLP-1 drugs combined.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events, including nausea and vomiting, were significantly more frequent with GLP-1RA treatment
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458006
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 1 diabetes and overweight or obesity, pooled GLP-1 receptor agonists did not increase serious adverse events.
In plain wordsIn adults with type 1 diabetes and overweight, serious side effects did not increase with GLP-1 drugs combined.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
no increase in serious adverse events was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible studies included adults with T1D, body mass index ≥25 kg/m², and GLP-1RA treatment alongside insulin for ≥12 weeks.
Summary · context
Exactly 13 studies met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4133458007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.